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INTRODUCTION
Urolithiasis is a complex condition with many etiologies.1
Vast majority of stones are either calcium containing
(oxalate and phosphate) or uric acid.2 There are various
clinical, biochemical, metabolic, and genetic charac-
teristics of the inherited diseases which lead to
nephrolithiasis/nephrocalcinosis, such as: Idiopathic
hypercalciuria, renal hypophosphatemia, renal tubular
acidosis, idiopathic infantile hypercalcemia, Dent
disease, familial hypomagnesemia with hypercalciuria
and nephrocalcinosis, hypocitraturia, cystinuria, primary
hyperoxaluria and renal hypouricemia.3 The term
urolithiasis in itself, groups multitude of stones each with
some common and other discrete etiologies. Diet,
presence of metabolic syndrome, and some genetic
abnormalities are major causes of recurrent urolithiasis.
Several factors may be related to susceptibility to urinary
lithiasis such as race, gender, dietary intake, genetics,
climatic aspects, and metabolic changes.4
Urolithiasis is a highly recurrent condition. The lifetime
risk of developing stone is 1 in10,5 compared to a risk of
9 in 10 for recurrence at 10 years.6 It is characterized by
a recurrence rate around 50%,7 reaching 70% within 10
years. Careful history and metabolic evaluation are the
key to prevention strategies. However, prevention
strategies and metabolic evaluation is one of the most
controversial areas in stone management.8 A recent
survey by McGuire and colleagues8 in North American
urologists noted that practices in the metabolic
investigation of stone-forming patients demonstrate
wide ranging variations. This is partly because metabolic
evaluation and then interpretation is cumbersome, it is
expensive and then often there are no clear answers,
particularly in mixed stones, long-term medical therapy;
and life-style modifications have poor compliance and
partly because there is insufficient strong evidence that
for most stones, medical therapy significantly impact
stone recurrence. Although there is a dearth of strong
scientific evidence for the benefit of selective versus
non-selective prevention of recurrence in patients with
calcium stone disease, there is currently both convincing
and logical information in support of tailored/selective
treatment regimens aiming at correction of abnormal
target variables.9 The poor results of metaphylaxis are
partly due to low and diminishing long-term compliance
to the intervention, although strict adherence has been
shown to prevent chronic kidney disease.10 It is,
therefore, imperative to have a tailored approach to
target patients at most risk of recurrence.
Urolithiasis management has become less invasive with
the introduction of lithotripsy and endourology. Minimally,
invasive options on one hand have made management
of urolithiasis less morbid intervention. However, it has
downside. The keenness to do metabolic and long-term
medical interventions are partly dampened by advances
in endourology. Sininsky et al. noted that low education,
high poverty, and younger age are associated with
suboptimal evaluation follow-up.11 Of note, the lowest
adherence was in younger patients, a population that
requires the most urgent workup.
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The training of urologists in metabolic evaluation and
interpretation is also lacking. It is, therefore, not surprising
that urologist managing stones, have issues in
interpretation and ordering appropriate dietary and
medical advice. As a consequence, often the metabolic
workup is either not ordered or not followed-up. It is
important to develop tailored approach to order and
follow metabolic evaluation of patients, treated recently
for urolithiasis. Urological association guidelines have
consistently underscored the importance of urologists to
be involved in the metabolic evaluation and follow-up of
stone patients. The EAU guidelines recommend use of
general measures for patients with low risk for
recurrence, and specific metabolic interventions for
patient at high risk for recurrence.12 An AUA guideline
recommends that clinician should perform a screening
evaluation consisting of a detailed medical and dietary
history, serum chemistries and urinalysis on a patient
newly diagnosed with kidney or ureteral stones.13
Twenty-hour urinary estimation of super saturation of
various salts is implicated in stone formation. Dietary
and life-style modifications are recommended for most
stone formers; however, additional use of medical
management is directed for specific metabolic
abnormalities.
In view of the highly recurrent nature of this condition, it
is logical to have strategies for prevention. The major
debate in urology is to do or not to do metabolic workup.
There is a controversy as to how much information is
given to patients on prevention. Due to multiple factors,
most patients receive no or fragmented information on
prevention, often the metabolic abnormalities differ
significantly in repeat analysis.14 The factors for lack
of metabolic evaluation and implementation of
recommendations are attributable to both the physicians
(urologists) and patients. Most urologists are reluctant to
recommend metabolic workup and refer patient for
metaphylaxis. This is partly due to the poor understanding
of the biochemistry of urolithiasis; as most are not
convinced that prevention strategies work, and think that
with modern endourological means it is easier to treat
stone. In long-term, the results obtained with preventive
interventions is disappointing. Patients are motivated
following a recent painful episode of urolithiasis,
however, long-term compliance is poor.
The current writeup is aimed to define a tailored
approach to ordering and implementing metabolic
workup and suggests life-style modifications to decrease
the rate of recurrence for urolithiasis.
DISCUSSION
Why to do metabolic workups for stone patient?:
Metabolic workup for stone patients is performed to
identify potential anomalies, to identify if stone is
secondary to specific disorder, and to identify risk factors
contributing to urolithiasis. Urolithiasis is a complex
medical condition. It is not only related to various
metabolic and biochemical errors, but to some generic
medical conditions like metabolic syndrome. The workup
is clinical, radiological and biochemical evaluation. With
this comprehensive evaluation, it is possible to establish
a preventive intervention strategy.
There is often an argument in favour and against
metabolic workup. The proponents of metabolic workup
propose screening as urolithiasis is a highly recurrent
condition. Screening also helps to define and correct a
metabolic error. However, since urolithiasis is a common
condition, it is likely to put an enormous financial and
manpower burden on the healthcare system. In France,
the annual budget impact for stone disease based on
65 million inhabitants is €590 million for the payer.15 The
budget impact analyses show that prevention of
nephrolithiasis can have a significant cost savings for a
payer in a healthcare system and reduce the stone
burden significantly. However, opponents of metabolic
workup contend that the metabolic workup and
evaluation is expensive, strenuous and difficult to
interpret. In addition, there are few trials showing that
there is benefits of a pharmacological approach in stone
prevention.
Stone former classification and risk stratification:
Most adults’ first time stone formers (first episode of
documented stone disease) are likely not to form
another stone in their lifetime; particularly, if they are not
at high risk for an stone event. Recurrent stone formers
(previous documented history of urolithiasis) are,
however, at a much higher risk for recurrence. In
comparison pediatric patients are considered high risk
even following first event of urolithiasis. Certain stone
formers are at high risk from a stone event and therefore,
even with first event they should undergo defined
preventive strategy. These are patients with bilateral
stones disease, solitary kidney, anatomical anomalies,
obstructive pyelonephritis, or stone during pregnancy,
renal insufficiency or inflammatory bowel disease.
From stone analysis to preventive strategy: The EAU
guidelines on urolithiasis describe the development of
preventive strategy, based on stone analysis and risk
factors. Reliable stone analysis and basic metabolic
evaluation are highly recommended in all patients after
stone passage (grade A recommendation).12 Every
patient should be assigned to a low- or high-risk group
for stone formation. Patients with whewellite stones are
frequently seen with hyperoxaluria and medullary
sponge kidney, whereas wedillite are associated with
hypercalciuria. In patients with uric acid stones, the
causal factors could be low urinary pH, hypercalciuria,
and high uric acid output. The carbapatite is more often
associated with high urinary pH, hypercalciuria, and
primary hyperoxaluria. The brushite stones are seen in
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patients with primary hyperoxaluria, hypercalciuria and
sponge kidney. The second most important factor is
identification of the risk factors following stone
composition. Specific metabolic workups and preventive
strategies can be instituted, which are likely to be cost
effective.
Common stone types and metabolic abnormalities:
Calcium stones are the commonest stone type. About
80% of stones are calcium-containing stones. Urinary
super saturation is often observed in these patients for
calcium oxalate and calcium phosphate. The associated
metabolic abnormalities include hyper-oxaluria,
hypocitraturia, persistently elevated urine pH, and
increased urinary uric acid excretion. However, the most
common abnormality is idiopathic hypercalciuria (IH).
Spivacow et al.16 noted 57% to be having IH in a cohort
of 3,040 patients with urolithiasis. Treatment of IH is
often with thiazide diuretics. Several RCTs have shown
that the stone recurrence is decreased with the use of
thiazide for IH.17
The protective effects of citrate in urine on urolithiasis
are well known. It not only chelates calcium ions but also
prevent nucleation and growth at the crystal surface.
Barcelo and colleagues18 compared the efficacy of
potassium citrate with placebo in patients with hypo-
citraturic CaOx stones.18 In 3 years of follow-up in
patients taking potassium citrate, they noted a significant
reduction in stone formation rate from 1.2 to 0.1 per
patient-year (p<0.001). Patients with normal urinary
citrate level may also benefit from citrate supple-
mentation due to lowered calcium oxalate super
saturation and subsequent crystallisation.19
Hyperoxaluria is another common metabolic derangement;
of the various types of hyperoxaluria, idiopathic variety is
commonest. It is often due to excessive oxalate intake in
the diet, decreased dietary calcium, or increased
endogenous production. Dietary advises of cutting
oxalate-rich diet and taking recommended calcium, to
help binding oxalate in the gut, are reasonable advises.
Calcium phosphate stones are frequently found as
mixed stones with CaOx. They typically constitute <50%
of the stones. Pure calcium phosphate stones are
associated with renal acid excretion defect, most
commonly due to distal RTA. The treatment strategies
are similar to CaOx, i.e. reduced dietary sodium and
protein, high fluid intake, and may be thiazides and
citrate.
Uric acid stones are formed in patients with low urine
pH, low urine volume and hyperuricosuria, of which the
former is the most common cause. Urinary alkalization
with potassium citrate and curtailing animal protein
intake to less than 20 g/kg/day and in refractory cases of
hyperuricemia allopurinol or febuoxstat can be added.
Struvite stones and infection stones or magnesium
ammonium phosphate stones are seen in patients with
infection from urea-splitting bacteria such as Proteus,
Providencia; and sometimes Klebsiella, Pseudomonas,
and Enterococci. Staghorn stones are treated by
interventional treatment including endourology and
lithotripsy, following culture specific antibiotics. Only
small residual stones can be eradicated by minimising
urease concentration.20 Long-term, low dose culture-
specific antimicrobials are important to prevent new
stone growth and progression, after surgery.
In most series, 10% stones are infection stones. They
are characterised by high recurrence rate and are more
commonly seen in women, boys and elderly patients.
They have a very rapid growth rate and can recur in 4-6
weeks.21 The chemical composition of infection stone is
carbonate-apatite. Following interventional treatment of
stone, these patients would require long-term antibiotics
(~3 months) either culture-sensitive or flouroquinolones.
Use of urease inhibitor acetylhydroxamic acid is also
recommended along with acidification of urine.
Cysteine stones results from cystinuria, which is an
autosomal recessive disorder of renal tubular and
intestinal transport of dibasic amino acids, with
consequent increased urinary excretion of cysteine,
ornithine, lysine and arginine. Treatment of cystinuria is
by increasing fluids, using alkalinising agents (to
maintain urine pH at around 7), chelation therapy and
decreasing salt and protein in the diet.
Risk stratification of patients with urolithiasis: The
EAU guidelines recommend stone analysis and basic
metabolic workup for all patients; however, classify
patients into high versus low risk for stone recurrence for
intervention to decrease recurrence.16 Those at high risk
for recurrence are recommended to have detailed
workup and specifically treated for decreasing stone
recurrence, whereas low risk patients should at least
follow the general measures.22
Stone at young age and those with family history are
considered at risk. Certain stone compositions like
brushite, uric acid and urate containing and infectious
stone are also highly recurrent types. Genetic disorders
like cystinuria, pH, distal RTA, xanthinuria, and Lesch-
Nyhan syndrome are also associated with frequent
stone recurrence. Patients with hyperparathyroidism,
nephrocalcinosis, following by intestinal pass and
bariatric surgery are predisposed to recurrent
urolithiasis. Structural abnormalities of urinary tract like
ureteropelvic junction obstruction horseshoe kidney,
medullary sponge kidney, and ureterocoele again results
in stasis and consequent recurrent urolithiasis.
Workup for stone former: Following a basic clinical
workup with detailed history (focusing particularly on
dietary habits and family history) and physical
examination, urinalysis, creatinine serum calcium
(corrected values), and uric acid should be done for all
patients. Stone analysis using FTIR or X-ray diffraction
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is highly recommended. Stone composition varies in
episodes; therefore, it should be done each time for
person passes stone. Patients at high risk of recurrence
should undergo further detailed metabolic workup.
Fourier transform infrared spectroscopy (FTIR) is a
method of stone analysis, which gets to the core of the
stone. With the help of FTIR, a semi-quantitative
methodology or analysis is done from all identifiable
layers of the stone. Unlike previous laboratory practices,
composition of stone core (nidus) is reported in stones
that can be sliced, separately from the composition of
the body of the stone. The composition of the core may
be entirely different from that of the peripheral layers and
suggests the formative cause of the stone. This gives
the treating physician a greater insight and broader
vision in determining the cause of stone formation; and
helps in decision-takings for treatment, and future prevention.
FTIR compares the results with a basic library of multiple
spectra of pre-analysed synthetic kidney stone samples.
This data of synthetic samples are prepared by mixing
various combinations of pure standard materials. The
results include a reliability factor for the analysis, which
can be stored with the sample spectrum. The software
provides features that allow the laboratory to easily
display and compare the spectrum of the unknown
sample along with the library reference spectrum.
CONCLUSION
Risk stratification and determination of stone composition
can help in defining a structured approach to the
detailed metabolic workup. This tailored approach will
help in identifying patients with more detailed workup in
those who are more likely to benefit from metabolic
evaluation. Children, however, are different as they are
likely to recur; and all children with stones need
assessment to develop a preventive strategy. As a rule,
the earlier a child forms a stone, more likely it is that
another stone will ensue in the lifetime of the child.
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